In contrast, GLP-2 enhances intestinal growth as well as nutrient digestion, absorption and barrier integrity [61], and GLP-2-based therapeutics are currently used to treat patients with intestinal failure consequent to short bowel syndrome [61]. The gene discussed is GCG; the disease is short bowel syndrome.